APA

Nakamura R., Rodriguez R., Palmer J., Stein A., Naing A., Tsai N., Chang K., Slovak M. L., Bhatia R., Spielberger R., Kogut N., Pullarkat V., Kirschbaum M., Forman S. J. & O'Donnell M. R. (20071219). Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. : Bone marrow transplantation.

Chicago

Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak M L, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman S J and O'Donnell M R. 20071219. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. : Bone marrow transplantation.

Harvard

Nakamura R., Rodriguez R., Palmer J., Stein A., Naing A., Tsai N., Chang K., Slovak M. L., Bhatia R., Spielberger R., Kogut N., Pullarkat V., Kirschbaum M., Forman S. J. and O'Donnell M. R. (20071219). Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. : Bone marrow transplantation.

MLA

Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak M L, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman S J and O'Donnell M R. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. : Bone marrow transplantation. 20071219.